The stock of Motif Bio PLC (LON:MTFB) is a huge mover today! The stock increased 2.36% or GBX 0.81 on November 11, hitting GBX 35.31. About 246,541 shares traded hands or 53.12% up from the average. Motif Bio PLC (LON:MTFB) has declined 14.16% since April 13, 2016 and is downtrending. It has underperformed by 20.30% the S&P500.
The move comes after 9 months positive chart setup for the GBX 38.88 million company. It was reported on Nov, 11 by Barchart.com. We have GBX 74.15 PT which if reached, will make LON:MTFB worth GBX 42.77M more.
Motif Bio PLC (LON:MTFB) Ratings Coverage
Out of 2 analysts covering Motif Bio Plc (LON:MTFB), 1 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 50% are positive. Motif Bio Plc has been the topic of 40 analyst reports since July 23, 2015 according to StockzIntelligence Inc. The stock has “Speculative Buy” rating given by Beaufort Securities on Monday, October 19. Northland Capital maintained Motif Bio PLC (LON:MTFB) rating on Wednesday, January 6. Northland Capital has “Buy” rating and GBX 114 price target. On Tuesday, December 15 the stock rating was maintained by Northland Capital with “Buy”. The stock of Motif Bio PLC (LON:MTFB) has “Buy” rating given on Tuesday, August 9 by Northland Capital. The firm has “Speculative Buy” rating by Beaufort Securities given on Wednesday, September 30. The stock of Motif Bio PLC (LON:MTFB) has “Buy” rating given on Thursday, July 23 by Northland Capital. The rating was maintained by Beaufort Securities with “Speculative Buy” on Wednesday, December 16. The rating was maintained by Beaufort Securities on Wednesday, October 14 with “Speculative Buy”. Northland Capital maintained Motif Bio PLC (LON:MTFB) on Wednesday, March 2 with “Buy” rating. The firm earned “Speculative Buy” rating on Thursday, March 3 by Beaufort Securities.
Another recent and important Motif Bio PLC (LON:MTFB) news was published by Uk.Finance.Yahoo.com which published an article titled: “Motif Bio Plc (MTFB.L)” on April 02, 2015.
Motif Bio plc is a clinical-stage biopharmaceutical company. The company has a market cap of 38.88 million GBP. The Firm is engaged in development of antibiotics, which are designed for treatment of infections caused by multi-drug resistant bacteria. It currently has negative earnings. It operates in the development and commercialization of pharmaceutical formulations segment.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.